Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin
- 1 September 1995
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 62 (3), 339-347
- https://doi.org/10.1016/0304-3959(95)00011-g
Abstract
Topically applied acetylsalicylic acid (ASA), salicylic acid (SA) and indomethacin were tested in an experimental pain model that provides direct nociceptor excitation through cutaneous tissue acidosis. In 30 volunteers, sustained burning pain was produced in the palmar forearm through a continuous intradermal pressure infusion of a phosphate-buffered isotonic solution (pH 5.2). In 5 different, double-blind, randomized cross-over studies with 6 volunteers each, the flow rate of the syringe pump was individually adjusted to result in constant pain ratings of around 20% (50% in study 4) on a visual analog scale (VAS). The painful skin area was then covered with either placebo or the drugs which had been dissolved in diethylether. In the first study on 6 volunteers, ASA (60 mg/ml) or lactose (placebo) in diethylether (10 ml) was applied, using both arms at 3-day intervals. Both treatments resulted in sudden and profound pain relief due to the cooling effect of the evaporating ether. With lactose, however, the mean pain rating was restored close to the baseline within 6–8 min while, with ASA, it remained significantly depressed for the rest of the observation period (another 20 min). This deep analgesia was not accompanied by a loss of tactile sensation. The further studies served to show that indomethacin (4.5 mg/ml) and SA (60 mg/ml) were equally effective as ASA (each 92–96% pain reduction) and that the antinociceptive effects were due to local but not systemic actions, since ASA and SA did not reach measurable plasma levels up to 3 h after topical applications. With a higher flow rate of acid buffer producing more intense pain (VAS 50%), ASA and SA were still able to significantly reduce the ratings by 90% or 84%, respectively. On the other hand, by increasing the flow rate by a factor of 2 on average, during the period of fully developed drug effect it was possible to overcome the pain suppression, which suggests a competitive mechanism of (acetyl-) salicylic antinociception.Keywords
This publication has 25 references indexed in Scilit:
- Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.Circulation, 1993
- Effect of Sodium Salicylate on the Human Heat Shock ResponseScience, 1992
- A new topical treatment for acute herpetic neuralgia and post-herpetic neuralgia: the aspirin/diethyl ether mixture. An open-label study plus a double-blind controlled clinical trialPain, 1992
- Protons activate a cation conductance in a sub‐population of rat dorsal root ganglion neurones.The Journal of Physiology, 1991
- Randomised double-blind study of topical capsaicin for treatment of post-herpetic neuralgiaPain, 1990
- TOPICAL LOCAL ANAESTHETICS AND HERPES SIMPLEXThe Lancet, 1989
- Treatment of chronic postherpetic neuralgia with topical capsaicin: A preliminary studyJournal of the American Academy of Dermatology, 1987
- The antagonism between salicylate-induced and pH-induced changes in the membrane conductance of molluscan neuronsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1972
- Absorption of Some Organic Compounds Through the Skin in ManJournal of Investigative Dermatology, 1970
- Limiting factors in experimental painJournal of Chronic Diseases, 1956